An improved steroid sulfatase inhibitor was prepared by replacing the N-propyl group of the second-generation steroid-like inhibitor (2) with a N-3,3,3-trifluoropropyl group to give (10). This compound is 5-fold more potent in vitro, completely inhibits rat liver steroid sulfatase activity after a single oral dose of 0.5 mg/kg, and exhibits a significantly longer duration of inhibition over (2). These biological properties are attributed to the increased lipophilicity and metabolic stability of (10) rendered by its trifluoropropyl group and also the potential H-bonding between its fluorine atom(s) and Arg 98 in the active site of human steroid sulfatase. Like other sulfamates, (10) is expected to be sequestered, and transported by, erythrocytes in vivo because it inhibits human carbonic anhydrase II (hCAII) potently (IC 50 , 3 nmol/L). A congener (4), which possesses a N-(pyridin-3-ylmethyl) substituent, is even more active (IC 50 , 0.1 nmol/L). To rationalize this, the hCAII-(4) adduct, obtained by cocrystallization, reveals not only the sulfamate group and the backbone of (4) interacting with the catalytic site and the associated hydrophobic pocket, respectively, but also the potential H-bonding between the N-(pyridin-3-ylmethyl) group and NE 2 of Gln 136 . Like (2), both (10) and its phenolic precursor (9) are non-estrogenic using a uterine weight gain assay. In summary, a highly potent, long-acting, and nonestrogenic steroid sulfatase inhibitor was designed with hCAII inhibitory properties that should positively influence in vivo behavior. Compound (10) and other related inhibitors of this structural class further expand the armory of steroid sulfatase inhibitors against hormone-dependent breast cancer. [Mol Cancer Ther 2008;7(8):2435 -44] 
Introduction
Endocrine therapy is an effective form of treatment for hormone-dependent breast cancer. A new form of endocrine therapy is emerging clinically that would deliver estrogen deprivation via a distinct and novel mechanism. This involves the inhibition of the production of estrogenic steroids via the steroid sulfatase pathway.
Steroid sulfatase catalyzes the hydrolysis of steroid sulfates such as estrone-3-sulfate and dehydroepiandrosterone sulfate to estrone (E1) and dehydroepiandrosterone, respectively. E1, which is the main source of estrogens in tumors (1) , can be converted to estradiol, the estrogen that binds to the estrogen receptor with high affinity, by 17h-hydroxysteroid dehydrogenase type 1. Dehydroepiandrosterone can also be reduced by this enzyme to androstenediol, which, although an androgen, can bind to the estrogen receptor and stimulate the growth of hormonedependent cancer cells in vitro and support the growth of carcinogen-induced mammary tumors in vivo in rodents (1, 2) . Dehydroepiandrosterone can also be converted to androstenedione which is the main substrate for aromatase in postmenopausal women (3) . Hence, steroid sulfatase inhibitors, when used alone or in concert with an aromatase inhibitor, may enhance the response of hormone-dependent breast tumors to this type of endocrine therapy by reducing not only the formation of E1 from estrone-3-sulfate but also the synthesis of other steroids with estrogenic properties such as androstenediol.
Many structurally diverse steroid sulfatase inhibitors were developed in the past decade, of which the most successful candidates are those bearing the pharmacophore for potent irreversible inhibition [an aryl sulfamate group (Ar-OSO 2 NH 2 )]. These compounds characteristically inhibit steroid sulfatase in a time-and concentration-dependent manner. Although the very first potent steroid sulfatase inhibitor reported is estrone-3-O-sulfamate (EMATE; Fig. 1 ), this agent was not developed because it was highly estrogenic in rodents (4) . This undesirable property stimulated the development of nonsteroidal mimics, which led to the discovery of STX64 (BN83495; Fig. 1 ), the ''firstin-class'' steroid sulfatase inhibitor that recently underwent a phase I trial (3) . STX64, a tricyclic agent that exhibits excellent efficacy in various in vivo tumor models (5 -7) , has shown promising results in treated postmenopausal patients with advanced breast cancer (3, 8) .
Despite success in developing nonsteroidal steroid sulfatase inhibitors, many efforts were also made in parallel to overcome the drawbacks of EMATE. The most notable strategies include the modification of its ring system or the introduction of substituent(s) at various positions of its steroidal scaffold to give derivatives that are nonestrogenic but remain highly potent against steroid sulfatase and are orally active (1) . Two steroid-like inhibitors, (2) and (4) (Fig. 1) , developed by our group with an expanded D-ring possess such desirable properties (9, 10) . In a placental microsome preparation, both compounds (IC 50 values, 1 nmol/L) inhibit steroid sulfatase 18-fold more potently than EMATE (9) . In vivo, after an oral dose of 10 mg/kg/d for 5 days, both inhibitors inhibit liver steroid sulfatase activity in ovariectomized rats by 99%. Using a uterine weight gain assay, both inhibitors are devoid of estrogenic activity, unlike EMATE (10) .
In a recent in vivo study where the efficacy of STX64 and (2) were compared side-by-side, both inhibitors at doses of 1 and 10mg/kg inhibit rat liver steroid sulfatase activity by >95%, but the duration of inhibition observed for (2) was found to be significantly longer. Therefore, after a single oral dose of 10 mg/kg, the time taken for liver steroid sulfatase activity to recover by 50% was 4 days with STX64 compared to 12 days with (2) where complete recovery was only observed by day 15 (6) . EMATE was also found to exhibit similar prolonged inhibitory activity in vivo (11), unlike STX64.
That some steroidal steroid sulfatase inhibitors could be long-acting in vivo highlights a distinction between the second-generation steroid sulfatase inhibitor (2) and STX64 pharmacokinetically. Although the majority of modern therapeutics in oral dosage form is designed to be given on a once-a-day basis, there may be pharmaceutical advantages, in particular with regard to patient compliance, for an orally active drug to be administered on a weekly or biweekly interval.
To explore the feasibility of further prolonging the duration of action of (2), we modified its structure by replacing the N-propyl with a N-3,3,3-trifluoropropyl group to give (10) (Fig. 2) . It was reasoned that the terminal methyl group of (2) is potentially a metabolically vulnerable site; hence, its fluorination may prolong in vivo activity of (10) . The in vitro activity of (10) was studied in JEG-3 cells and the extent to which rat liver steroid sulfatase activity is inhibited and recovers after dosing of (2) and (10) was determined. A uterine weight gain assay was carried out to assess the estrogenicity of (10) and other related derivatives. To explore how (10) may interact with human steroid sulfatase, it was docked into the crystal structure reported by Hernandez-Guzman et al. (12) . As an illustration for this structural class of steroid sulfatase inhibitors, the ability of (2), (4), and (10) to interact with human carbonic anhydrase II (hCAII) was investigated including a structural study for (4).
Materials and Methods

Chemistry
All chemicals and organic solvents of A.R. grade were either purchased from Aldrich or Fisher Scientific. Sulfamoyl chloride was prepared as described by Woo et al. (13) . TLC was done on precoated plates (Merck TLC aluminum sheets silica gel 60 F 254 , art. no. 5554). Product(s) and starting material were detected by either viewing under UV light or treating with an ethanolic solution of phosphomolybdic acid followed by heating. Flash column chromatography was done on silica gel (Matrex C60 To a solution of (5) (36.0 g, 0.10 mol) in tetrahydrofuran (THF) (600 mL) and methanol (2.0 L) was added solutions, dropwise and simultaneously, of iodine (72 g, 0.28 mol) in methanol (500 mL) and potassium hydroxide (130 g, 2.3 mol) in water (200 mL), so that the solution remained orange (f180 mL/h I 2 and 30 mL/h KOH). Once the additions were complete, the reaction mixture was stirred at room temperature overnight then concentrated and poured into water (800 mL). After acidification with 5 mol/L HCl and extraction with ethyl acetate (3 Â 200 mL), the combined organics were washed with aqueous sodium thiosulfate and water (each 2 Â 200 mL) and then evaporated. The resulting orange foam was dissolved in a solution of KOH (56 g, 1 mol) in methanol/water (2:1; 800 mL) and the mixture was refluxed for 4 h. The final brown solution was concentrated and poured into water (500 mL). After acidification with 5 mol/L HCl and extraction with ethyl acetate (3 Â 200 mL), the combined organics were washed with water and brine (each 2 Â 200 mL) then dried (MgSO 4 ) and evaporated. The resulting orange solid was recrystallized from chloroform/hexanes (5:3) to give (6) as a cream powder (33.9 g, 83%): mp, 211-214jC. The analytical data of the product were the same as those described by Fischer et al. (9) .
To a solution of (7) (9) (2.0 g, 5.14 mmol) in anhydrous acetonitrile (250 mL) was added potassium carbonate (780 mg, 5.66 mmol), potassium iodide (100 mg), 18-crown-6 (2.98 g, 11.31 mmol), and 3-bromo-1,1,1-trifluoropropane (1.61 g, 10.3 mmol) and the reaction mixture was heated at 82jC for 24 h. After cooling and evaporation of the acetonitrile, the resulting orange foam was redissolved in ethyl acetate (200 mL), washed with brine (2 Â 200 mL), dried (MgSO 4 ), filtered, and evaporated. A solution of (8) (1.10 g, 2.27 mmol) with 10% Pd/C (100 mg) in methanol (40 mL) and THF (40 mL) was stirred under an atmosphere of hydrogen for 3 h. After removal of the catalyst by filtration, evaporation of the solvent gave a white solid. Recrystallization (diethyl ether/hexanes) gave (9) (10) A solution of sulfamoyl chloride in toluene (f0.6 mol/L, 5.80 mL, 3.50 mmol) was evaporated in vacuo at room temperature. The resulting white solid was dissolved in anhydrous N,N-dimethylacetamide (5 mL) and cooled to 0jC under nitrogen. To this stirred solution was added in a dropwise manner a solution of (9) (550 mg, 1.39 mmol) in N,N-dimethylacetamide (5 mL). The reaction was then allowed to warm to room temperature overnight. The light brown suspension obtained on dilution with ethyl acetate (50 mL) was washed with saturated aqueous ammonium chloride solution (3 Â 50 mL) and brine (50 mL) and then dried (MgSO 4 ), filtered, and evaporated in vacuo. To the resulting gum in the minimum amount of dichloromethane (5 mL) was added diethyl ether (25 mL) followed by hexanes (100 mL) in small portions to initiate precipitation. Recrystallization (dichloromethane/hexanes) of the precipitate collected gave (10) (10) was constructed using SYBYL7.1 (Tripos Associates), which was optimized using the Tripos force field and Powell algorithm terminating at a gradient of 0.05 kcal/mol/Å with partial charges calculated using the Gasteiger-Hü ckel method. The X-ray structure of human steroid sulfatase (Protein Data Bank accession code 1P49) was prepared for docking using the following procedure: waters of crystallization were removed from the structure. The catalytic amino acid FGS75 (formylglycine) was converted to the gem-diol form using SYBYL7.1 structure editing tools. Hydrogen atoms were built onto the structure and optimized using the Tripos force field and Powell algorithm with Gasteiger-Hü ckel charges. Compound (10) was docked into steroid sulfatase a total of 20 times using the GOLD docking program version 3.1.1 (14) with the GOLDScore fitness function. The active site of the enzyme was defined as a 20 Å sphere around the Ch atom of amino acid 75.
Biology In vitro. JEG-3 cells were seeded into 24-well culture plates and maintained in MEM (Flow Laboratories) containing growth supplements and used when 80% confluent. For assaying steroid sulfatase activity, cells were incubated with [6,7- 3 H]estrone-3-sulfate (5 pmol, 7 Â 10 5 dpm, 60 Ci/mmol; Perkin-Elmer) in the absence or presence of Figure 3 . Docking of (10) into the crystal structure of human steroid sulfatase as reported by HernandezGuzman et al. (12) . Coordinating Ca 2+ atom (purple ), formylglycine in its gem -diol form, and several amino acids of interest.
(0.001-10,000 nmol/L) inhibitor. The product, E1, was separated from estrone-3-sulfate by toluene partition, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]E1 was used to monitor procedural losses and radioactivity was measured by liquid scintillation spectrometry.
In vivo. Female adult Wistar rats (180-200 g) were purchased from Charles River UK. Experiments were carried out under conditions that complied with institutional requirements. Groups of three rats each received a single oral dose of either vehicle (10% THF; 90% propylene glycol) or steroid sulfatase inhibitor at 0.1, 0.5, or 1.0 mg/kg. Twenty-four hours later, rats were terminally anesthetized and liver samples were taken and stored at -20jC. The recovery of liver steroid sulfatase activity after inhibition was also measured. In the recovery studies, rats were given a single dose of steroid sulfatase inhibitor at 10 mg/kg or vehicle control and then sacrificed at 1, 5, 10, 15, 21, and 28 days after dosing and their livers were removed for steroid sulfatase analysis (6) .
Uterine Weight Gain Assay. Ovariectomized female Wistar rats (200 g) were purchased from Charles River. Groups of three rats were treated with 10% THF/90% propylene glycol vehicle (p.o.), 1 Ag E1/rat (s.c. in 10% ethanol/90% propylene glycol) or orally with steroid sulfatase inhibitor at 10 mg/kg/d for 4 days. Animals were sacrificed 24 h after administration of the last dose of compound and uteri were removed, excised of fat, and weighed. Total body weights of the rats were also recorded, and the uterine weight was expressed as % total body weight.
hCAII Studies Inhibition constants were measured using a 96-well plate spectrophotometric assay. Assay contained hCAII (7 units/ mL; Sigma) and 1 mmol/L 4-nitrophenyl acetate in 50 mmol/L Tris-HCl (pH 7.8) in a final volume of 0.18 mL and were incubated for 20 min at 20jC. Stock solutions of inhibitor were prepared in THF.
Protein Crystallography Crystals of the hCAII-(4) complex were obtained by cocrystallization experiments, adding a 5-molar excess of inhibitor to a 10 mg/mL protein solution in 100 mmol/L Tris-HCl (pH 8.5). The precipitant solution contained 2.5 mol/L (NH 4 ) 2 SO 4 , 0.3 mol/L NaCl, 100 mmol/L TrisHCl (pH 8.2), and 5 mmol/L 4-(hydroxymercurybenzoic) acid to improve the crystal quality. Crystals grew within a few days and were isomorphous to those of the native enzyme (15) . A complete dataset was collected at 1.70 Å resolution at Synchrotron source Elettra in Trieste using a Mar CCD detector. The crystal belonged to the P2 1 space group with unit cell variables: a = 42.05 Å , b = 41.44 Å , c = 71.67 Å , and b = 104.35j. Diffracted intensities were processed using the HKL crystallographic data reduction package (Denzo/Scalepack; ref. 16 ). Data processing statistics are summarized in Supplementary Table S1 . 5 The structure of the complex was analyzed by difference Fourier techniques using the Protein Data Bank file 1CA2 (15) as a starting model for refinement. The refinement process was carried out with the program CNS (17), whereas the model building and map inspections were done using the O program (18) . Fourier maps calculated with (3Fo -2Fc) and (Fo -Fc) coefficients showed prominent electron density features in the active site regions. After initial refinement limited to the enzyme, inhibitor molecules were gradually built into the models for further refinement. Restraints on inhibitor bond angles and distances were taken from similar structures in the Cambridge Structural Database and standard restraints were used on protein bond angles and distances throughout refinement. The ordered water molecules were added automatically and checked individually. Each peak contoured at 3j in the |Fo| -|Fc| maps was identified as a water molecule, provided that hydrogen bonds would be allowed between this site and the model. The correctness of stereochemistry was finally checked using PROCHECK (19) . Final refinement statistics are reported in Supplementary Table S1 . 5 Coordinates and structure factors have been deposited with the Protein Data Bank (accession code 3C7P).
Results and Discussion
Chemistry
The method of Fischer et al. (9) was adopted, but slightly modified, for the synthesis of (10) (Fig. 2) . Due to the limited solubility of (5) in methanol at room temperature, which is a major drawback for performing the haloform reaction on a larger scale, (5) was dissolved in a mixture of THF/methanol (f1:3). The incorporation of THF as a cosolvent did not affect the progress of the haloform reaction but improved solubility of (5) by f5-fold.
Ring closure of the di-acid (6) with urea to the imide (7) (9) proceeded in 75% yield. However, unexpectedly the Nalkylation of (7) with 3-bromo-1,1,1-trifluoropropane in N,N-dimethylformamide at room temperature using sodium hydride as base gave no trace of the desired product (8) . Neither changing the base to potassium carbonate in acetonitrile in the presence of tetrabutylammonium iodide as a phase transfer catalyst nor even to 1.6 mol/L n-butyllithium in hexanes in anhydrous THF at À78jC produced a noticeable effect. One possible explanation for these findings is that chelation to the metal cation might reduce the nucleophilicity of the anionic imide. Hence, the reaction was repeated by heating with potassium carbonate as base under phase transfer conditions in the presence of 6 eq. of 18-crown-6. As anticipated, the N-alkylation of (7) with 3-bromo-1,1,1-trifluoropropane to give (8) was successful under these conditions. It is therefore likely that 18-crown-6 catalyzes the reaction by chelating the potassium cation, preventing it from coordinating with oxygen atoms of the imide ring and hence renders the resulting imido anion more effective as a nucleophile. Finally, sequential hydrogenation and sulfamoylation, using standard conditions, furnished the phenol (9) and sulfamate derivative (10), respectively, in good yield.
Biology In vitro Activity and Molecular Modeling Studies. The steroid sulfatase inhibitory activities of (2) and (10) in JEG-3 cells are tabulated in Table 1 . As shown, the IC 50 of (10) in JEG-3 cells is 35 F 5 pmol/L compared with 180 F 30 pmol/L of (2). Thus, the trifluoromethyl group of (10) renders a 5-fold increase in potency against steroid sulfatase in vitro.
It is a common phenomenon that an increase in lipophilicity is a key molecular variable for increasing nonspecific binding affinity of a ligand to its target protein.
When the ligand is an enzyme inhibitor, an increase in in vitro inhibitory activity is often expected when the lipophilicity of the inhibitor is increased. A widely used strategy in drug design for increasing the lipophilicity of a compound is by replacing a hydrogen with a fluorine atom. The trifluoromethyl (CF 3 ) group is among the most lipophilic of all small substitutents (20) . To compare the lipophilicity of (2) and (10), the widely used OSIRIS cLogP predictor (21) and XLOGP v 2 (22) programs were employed to determine cLogP values. The OSIRIS cLogP values obtained for (2) and (10) are 2.49 and 2.97, respectively, and XLOGP v 2 values are 2.44 and 3.44, respectively. Although both programs estimate a similar cLogP value for (2), the two values obtained for (10) differ by f0.5 unit. Despite the difference, it is evident that (10) is significantly more lipophilic than (2) .
To explore the role of the trifluoromethyl group in the increase in potency of (10) over (2), the inhibitor was docked as its monoanionic form (fOSO 2 NH -) into the active site of human steroid sulfatase using its crystal structure (12) . Figure 3 represents a putative enzymeligand complex prior to the presumed irreversible inactivation of steroid sulfatase elicited by (10) . As anticipated, (2) and (10), and their respective phenolic precursors (1) and (9) at an oral dose of 10 mg/kg for 4 d, on uterine growth in the ovariectomized rat. Mean F SD of triplicate measurements. (12) . [Compound (2) was also docked and found to display the same docking mode as (10) (data not shown)]. The trifluoromethyl group of (10) (10) is well placed in the ligandenzyme complex for undertaking hydrophobic interactions with these neighboring amino acid residues, and we suppose, according to its in vitro potency, that these interactions are stronger than those exerted by the methyl group of (2) . How this might affect the next mechanistic step presumed to be irreversible sulfamoylation of the enzyme is as yet unclear, but tighter binders may be more efficient subsequent inactivators.
In addition to the presumed nonspecific hydrophobic interactions, it is also interesting to note that there is one charged amino acid in the active site of steroid sulfatase, Arg 98 , which is at a distance of 3.2 Å from the trifluoromethyl group. Although it remains debatable, there is evidence to support a role for covalently bound fluorine to act as a hydrogen bond acceptor and to engage in dipolar interactions in protein-ligand complexes (20, 25 -29) . It has been suggested that C-FÁÁÁÁÁH-O and C-FÁÁÁÁÁH-N interactions of V2.5 Å might provide some beneficial stabilizing effects between a ligand and its target (25) . In Fig. 3 , although the distance (3.2 Å ) between the trifluoromethyl group and Arg 98 is close to the limit of what would be considered as geometrically compatible with a hydrogen bond, the contacts between fluorine atom(s) of (10) and the hydrogen bond donor Arg 98 in a dynamic situation might indeed be closer than in the static docking model. Similarly, potential dipolar interactions between the trifluoromethyl group and the amino acid are also conceivable. The docking results suggest that the electrostatic interactions provided by the trifluoromethyl group, in conjunction with an increase in lipophilicity, with the above caveats might contribute concertedly to the 5-fold increase in potency observed for (10) compared with (2) in vitro.
Derivatives of 17a-benzylestradiol bearing a 4 ¶-t-butyl, 3 ¶-bromo, or 4 ¶-benzyloxy substituent were found to be potent reversible steroid sulfatase inhibitors, showing IC 50 values in JEG-3 cells between 22 and 28 nmol/L (30, 31) . Because the steroid sulfatase inhibitory activity observed for these nonsulfamoylated compounds is attributed to their elevated hydrophobicity (OSIRIS cLogP values > 6), the phenolic precursor of (10) , that is, (9) (Fig. 2 , OSIRIS cLogP = 4.06), was also evaluated as a reversible steroid sulfatase inhibitor. As shown in Table 1 , (9) inhibits JEG-3 cells steroid sulfatase by 55% inhibition at 10 Amol/L, whereas (1), the hydroxyl parent compound of (2), which has an OSIRIS predicated cLogP of 3.58, inhibits steroid sulfatase activity in JEG-3 cells by 70% at the same concentration. These results suggest that a much elevated level of hydrophobicity, probably as high as those of 17a-benzylestradiol derivatives, is required for imparting significant reversible steroid sulfatase inhibition. As shown, replacement of the terminal methyl group in (1) with a trifluoromethyl group to give (9) has relatively little effect on activity. However, the enhancement rendered by the trifluoromethyl group is much more significant with the sulfamoylated derivatives of these hydroxyl compounds, that is, (2) and (10) . Positioning of these molecules in the active site and access to potential interactions could of course be subtly different for these compounds. As observed previously, the weak steroid sulfatase inhibitory activities of (1) and (9) further confirm the pivotal role of the sulfamate group in imparting potent steroid sulfatase inhibition.
In vivo Activity and Steroid Sulfatase Recovery Studies. The ability of (2) and (10) to inhibit rat liver steroid sulfatase activity 24 h after a single oral dose of either agent at 0.1, 0.5, and 1 mg/kg is shown in Fig. 4A . Both compounds inhibit steroid sulfatase almost completely even at 0.5 mg/kg. It is only at the lowest dose of 0.1 mg/kg where a small but significant difference is observed [48% for (10) versus 25% for (2)].
In addition to influencing chemical properties and the deposition of drugs, fluorine substitution can enhance the half-life of drugs (20) . Such an effect is most effectively achieved by fluorine substitution at the site of potential metabolic attack, as the strong carbon-fluorine bond is much more resistant to direct chemical attack (oxidation) by metabolizing cytochrome P450 enzymes. One tentative metabolically labile site to potential hydroxylation in (2) is its terminal methyl group of the N-propyl substituent. Therefore, by having a terminal trifluoromethyl moiety, (10) may be more resistant to phase I and II metabolism and hence have a longer duration of action.
When the recovery of liver steroid sulfatase activity was assessed after rats were given a single oral dose of either inhibitor at 10 mg/kg, both (2) and (10) emerge as longacting, with liver steroid sulfatase activity remaining completely inhibited by days 4 and 5 (Fig. 4B) . For (2), liver steroid sulfatase activity starts to recover from day 6 achieving a 50% recovery by around day 12 (t 1/2 ) and an almost complete recovery by day 15. In contrast for (10), the respective data are day 17 (t 1/2 ) and day 28 (complete recovery). From these results, it is clear that the trifluoromethyl group significantly extends the half-life of (10) in vivo relative to (2) . Although the mechanism for this prolonged activity of (10) remains to be fully elucidated, it is anticipated that, among other things, the trifluoromethyl group increases the metabolic stability of (10) .
Estrogenicity Studies. After showing that (10) is a highly potent steroid sulfatase inhibitor in vivo, it was therefore important to confirm that its terminal trifluoromethyl group does not unexpectedly introduce estrogenicity to the molecule. As shown in Fig. 4C , like (2), (10) does not cause an increase in uterine weight in the ovariectomized rat, confirming it to be nonestrogenic. According to the various mechanisms of action proposed by our group (1, 32, 33) , the immediate product released after the irreversible inactivation of steroid sulfatase by a sulfamatebased steroid sulfatase inhibitor is expected to be its erythrocytes. Compound (10) , and indeed other related steroid sulfatase inhibitors with similar properties, offers further possibilities for attacking hormone-dependent breast cancer through steroid sulfatase inhibition.
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